Analyst Conference Summaries

Biotechnology Investor Aids


conference date: to be announced

I first bought Verstem in December 2017 and will begin coverage with the Q1 2018 analyst conference.



Verastem (VSTM) is a clinical-stage biotechnology company specializing in cancer therapies.

Verastem web site



More Analyst Conference Pages:


Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2018 William P. Meyers